The Effects of Systemic Lupus Erythematous on Myocardial Infarctions

Authors

  • Dr. Almothana Aburumman, MD Loyola University, Chicago, USA

DOI:

https://doi.org/10.25255/jss.2025.14.1.1.23

Keywords:

Systemic Lupus Erythematosus, Myocardial Infarctions, Disease Susceptibility, Heart diseases

Abstract

Hypothesis: Patients with systemic lupus erythematosus are more susceptible to myocardial infarctions than unaffected individuals.

Methods: This paper study analyzed were carried out for ten papers obtained from several database platforms. The database platforms considered include; Cureus Journal of Medical Science, Google scholar, PubMed, British Medical Journal (BMJ), and National Centre for Biotechnology Information (NCBI) were analyzed. keywords such as (Myocardial Infarctions), (myocardial infarction) AND (Systemic lupus erythematosus) were used to search for articles. Additionally, papers of interest included Cohort study, Randomized Control Trials (RCTs), and Cross-sectional studies with the target study population.  Only articles viewable as full text were included.

Results: A total of ten quantitative articles that fell within the specific parameters were selected, of which eight studies were Cohort, two Randomized Control Trials, and one Cross-sectional. The findings pointed out that many parameters play an influencing role in increasing the odds of having myocardial infarctions MI. Nevertheless, most of the included papers directly inferred the existence of a demonstrated effect of Systemic Lupus Erythematosus (SLE) on increasing the susceptibility to having myocardial infarctions.

Conclusion: The findings supported the reviews’ hypothesis, indicating a positive correlation between SLE and MI in patients. That is, SLE is a natural and significant factor affecting MI occurrences.           

Downloads

Download data is not yet available.

Author Biography

Dr. Almothana Aburumman, MD, Loyola University, Chicago, USA

Almothana Aburumman

https://orcid.org/0009-0007-0457-8124

References

Ajeganova, S., Hafström, I., & Frostegård, J. (2021). Patients with SLE have a higher risk of cardiovascular events and mortality in comparison with controls with the same levels of traditional risk factors and intima-media measures, which is related to accumulated disease damage and anti-phospholipid syndrome: a case-control study over 10 years. Lupus Science & Medicine, 8(1), e000454. https://doi.org/10.1136/lupus-2020-000454

Ajeganova, S., Hafström, I., & Frostegåd, J. (2020). P160 Risk of CV events and mortality in SLE is associated with accumulated disease-damage, anti-phospholipid syndrome, and higher carotid intima-media thickness. https://doi: 10.1136/lupus-2020-eurolupus.202

Artola, R. T., Mihos, C. G., & Santana, O. (2016). Effects of Statin Therapy in Patients with Systemic Lupus Erythematosus. Southern medical journal, 109(11), 705–711. https://doi.org/10.14423/SMJ.0000000000000561

Aviña-Zubieta, J. A., To, F., Vostretsova, K., De Vera, M., Sayre, E. C., & Esdaile, J. M. (2017). Risk of Myocardial Infarction and Stroke in Newly Diagnosed Systemic Lupus Erythematosus: A General Population-Based Study. Arthritis Care & Research, 69(6), 849–856. https://doi.org/10.1002/acr.23018

Bhatnagar, P., Wickramasinghe, K., Wilkins, E., & Townsend, N. (2016). Trends in the epidemiology of cardiovascular disease in the UK. Heart, 102(24), 1945–1952. https://doi.org/10.1136/heartjnl-2016-309573

Chen, S. K., Barbhaiya, M., Fischer, M. A., Guan, H., Yoshida, K., Feldman, C. H., Costenbader, K. H., & Everett, B. M. (2019). Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Seminars in Arthritis and Rheumatism, 49(3), 389–395. https://doi.org/10.1016/j.semarthrit.2019.06.005

Chin, C. W. L., Chin, C.-Y., Ng, M. X. R., Le, T.-T., Huang, F.-Q., Fong, K.-Y., Thumboo, J., & Tan, R.-S. (2014). Endothelial function is associated with myocardial diastolic function in women with systemic lupus erythematosus. Rheumatology International, 34(9), 1281–1285. https://doi.org/10.1007/s00296-014-2968-4

Farooq, A., Ullah, A., Ali, F., Yasin, H., Amjad, W., & Pervaiz, M. (2017). Acute Myocardial Infarction in Young Systemic Lupus Erythematosus Patient with Normal Coronary Arteries. Cureus. https://doi.org/10.7759/cureus.1370

Fernández-Nebro, A., Rúa-Figueroa, Í., López-Longo, F. J., Galindo-Izquierdo, M., Calvo-Alén, J., Olivé-Marqués, A., Ordóñez-Cañizares, C., Martín-Martínez, M. A., Blanco, R., Melero-González, R., Ibáñez-Rúan, J., Bernal-Vidal, J. A., Tomero-Muriel, E., Uriarte-Isacelaya, E., Horcada-Rubio, L., Freire-González, M., Narváez, J., Boteanu, A. L., Santos-Soler, G., & Andreu, J. L. (2015). Cardiovascular Events in Systemic Lupus Erythematosus. Medicine, 94(29), e1183. https://doi.org/10.1097/md.0000000000001183

Gaipl, U. S., Munoz, L. E., Grossmayer, G., Lauber, K., Franz, S., Sarter, K., Voll, R. E., Winkler, T., Kuhn, A., Kalden, J., Kern, P., & Herrmann, M. (2007). Clearance deficiency and systemic lupus erythematosus (SLE). Journal of Autoimmunity, 28(2-3), 114–121. https://doi.org/10.1016/j.jaut.2007.02.005

Gustafsson, J. T., Herlitz Lindberg, M., Gunnarsson, I., Pettersson, S., Elvin, K., Öhrvik, J., Larsson, A., Jensen-Urstad, K., & Svenungsson, E. (2017). Excess atherosclerosis in systemic lupus erythematosus, A matter of renal involvement: Case control study of 281 SLE patients and 281 individually matched population controls. PLOS ONE, 12(4), e0174572. https://doi.org/10.1371/journal.pone.0174572

Holmqvist, M., Simard, J. F., Asplund, K., & Arkema, E. V. (2015). Stroke in systemic lupus erythematosus: a meta-analysis of population-based cohort studies. RMD Open, 1(1), e000168. https://doi.org/10.1136/rmdopen-2015-000168

Krittanawong, C., Luo, Y., Mahtta, D., Narasimhan, B., Wang, Z., Jneid, H., Tamis-Holland, J. E., Mahboob, A., Baber, U., Mehran, R., Wilson Tang, W. H., Ballantyne, C. M., & Virani, S. S. (2020). Non-traditional risk factors and the risk of myocardial infarction in the young in the US population-based cohort. IJC Heart & Vasculature, 30, 100634. https://doi.org/10.1016/j.ijcha.2020.100634

Lloyd-Jones, D., Adams, R. J., Brown, T. M., Carnethon, M., Dai, S., De Simone, G., Ferguson, T. B., Ford, E., Furie, K., Gillespie, C., Go, A., Greenlund, K., Haase, N., Hailpern, S., Ho, P. M., Howard, V., Kissela, B., Kittner, S., Lackland, D., & Lisabeth, L. (2010). Executive Summary: Heart Disease and Stroke Statistics—2010 Update. Circulation, 121(7), 948–954. https://doi.org/10.1161/circulationaha.109.192666

Lu, L., Liu, M., Sun, R., Zheng, Y., & Zhang, P. (2015). Myocardial Infarction: Symptoms and Treatments. Cell Biochemistry And Biophysics, 72(3), pp. 865–867. https://doi.org/10.1007/s12013-015-0553-4

Meszaros, Z. S., Perl, A., & Faraone, S. V. (2012). Psychiatric Symptoms in Systemic Lupus Erythematosus. The Journal of Clinical Psychiatry, 73(07), 993–1001. https://doi.org/10.4088/jcp.11r07425

Murai, K., Sakata, K., Gamou, T., Nagata, Y., Tada, H., Shimojima, M., Okada, H., Hayashi, K., & Kawashiri, M. (2019). Acute myocardial infarction in a patient positive for lupus anticoagulant: a case report. BMC Cardiovascular Disorders, 19(1). https://doi.org/10.1186/s12872-019-1153-9

Niranjan Ojha, & Dhamoon, A. S. (2022). Myocardial Infarction. Nih.gov; StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK537076/

Perry, J. C., Schuetz, T. M., Memon, M. D., Faiz, S., & Cancarevic, I. (2020). Anabolic Steroids and Cardiovascular Outcomes: The Controversy. Cureus, 12(7), e9333. https://doi.org/10.7759/cureus.9333

Reed, G. W., Rossi, J. E., & Cannon, C. P. (2017). Acute myocardial infarction. Lancet (London, England), 389(10065), 197–210. https://doi.org/10.1016/S0140-6736(16)30677-8

Samuelsson, I., Parodis, I., & Anan, C. (2018). PS8:153 Subtypes and location of myocardial infarctions in systemic lupus erythematosus. Poster Session 8: Registries and Cohorts. https://doi.org/10.1136/lupus-2018-abstract.196

Shah, M. A., Shah, A. M., & Krishnan, E. (2009). Poor Outcomes After Acute Myocardial Infarction in Systemic Lupus Erythematosus. The Journal of Rheumatology, 36(3), 570–575. https://doi.org/10.3899/jrheum.080373

Thygesen, K., Alpert, J. S., Jaffe, A. S., Simoons, M. L., Chaitman, B. R., White, H. D., Katus, H. A., Lindahl, B., Morrow, D. A., Clemmensen, P. M., Johanson, P., Hod, H., Underwood, R., Bax, J. J., Bonow, R. O., Pinto, F., Gibbons, R. J., Fox, K. A., Atar, D., & Newby, L. K. (2012). Third universal definition of myocardial infarction. Circulation, 126(16), 2020–2035. https://doi.org/10.1161/CIR.0b013e31826e1058

Tornvall, P., Göransson, A., Ekman, J., & Järnbert-Pettersson, H. (2021). Myocardial Infarction in Systemic Lupus Erythematosus: Incidence and Coronary Angiography Findings. Angiology, 72(5), 459–464. https://doi.org/10.1177/0003319720985337

Nived, O., Ingvarsson, R. F., Jöud, A., Linge, P., Tydén, H., Jönsen, A., & Bengtsson, A. A. (2020). Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE. Lupus science & medicine, 7(1), e000398. https://doi: 10.1136/lupus-2020-000398

White, H. D., & Chew, D. P. (2008). Acute myocardial infarction. The Lancet, 372(9638), 570–584. https://doi.org/10.1016/S0140-6736(08)61237-4

Zhao, L., Liu, X., Zhang, Y., Liang, X., Ding, Y., Xu, Y., Fang, Z., & Zhang, F. (2016). Enhanced cell survival and paracrine effects of mesenchymal stem cells overexpressing hepatocyte growth factor promote cardioprotection in myocardial infarction. Experimental cell research, 344(1), 30–39. https://doi.org/10.1016/j.ye

Downloads

Published

2024-12-09

How to Cite

Aburumman, A. (2024). The Effects of Systemic Lupus Erythematous on Myocardial Infarctions. Journal of Social Sciences (COES&Amp;RJ-JSS), 14(1), 1–23. https://doi.org/10.25255/jss.2025.14.1.1.23